HCM
CYTO

Harvey Capital Management’s Altamira Therapeutics Ltd CYTO Stock Holding History

Harvey Capital Management’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Hold
0
– -$136K – 79
2016
Q2 		– Hold
0
– – – 73
2016
Q1 		– Sell
-1
Closed -$356K – 74
2015
Q4 		$251K Hold
1
– – 0.1% 72
2015
Q3 		$241K Buy
+1
New +$383K 0.1% 75
2015
Q2 		– Hold
0
– – – 88

Other funds holding CYTO

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $27.4B AUM 24.17% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Harvey Capital Management's CYTO Position: Q3 2016 in Review

Harvey Capital Management held its Altamira Therapeutics Ltd (CYTO) position steady in Q3 2016 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #79.

Harvey Capital Management first reported a position in CYTO in Q3 2015 and has held it in 2 quarters since. The position peaked at $251K in Q4 2015. 3 funds tracked by Wall St. Rank hold CYTO as of Q3 2016.

  • Harvey Capital Management held 0 shares of Altamira Therapeutics Ltd worth $0 as of Q3 2016.
  • Harvey Capital Management left its Altamira Therapeutics Ltd share count unchanged in Q3 2016.
  • Altamira Therapeutics Ltd made up ﹤0.01% of Harvey Capital Management's portfolio in Q3 2016, its #79 holding.
  • Harvey Capital Management first reported a position in Altamira Therapeutics Ltd in Q3 2015 and has held it in 2 quarters since.
  • Harvey Capital Management's Altamira Therapeutics Ltd position peaked at $251K in Q4 2015.
  • 3 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q3 2016.

Based on Harvey Capital Management's 13F filing for Q3 2016, filed 9 Nov 2016.